Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.
Survodutide showed an 18.7% body-weight reduction at 46 weeks in a phase 2 trial, but long-term safety and effectiveness are still uncertain.
Where it sits
this study against the rest of the survodutide (bi 456906) corpusSummary and findings
Survodutide (BI 456906) is an investigational dual glucagon and GLP-1 receptor agonist for obesity. In a phase 2 trial, participants receiving a 4.8-mg dose experienced a mean body-weight reduction of 18.7% at 46 weeks compared to 2.3% with placebo. Adverse events were common and influenced by dose escalation.
Abstract
Survodutide (BI 456906) is an investigational once-weekly dual glucagon and Glucagon-like Peptide (GLP-1) receptor agonist being developed for obesity. In a phase 2 trial involving adults with a body mass index ≥27 kg/m<sup>2</sup> without diabetes, participants assigned to the 4.8-mg dose achieved a mean body-weight reduction of up to 18.7% at 46 weeks, compared with 2.3% with placebo. Its proposed mechanism combines reduced food intake through GLP-1 receptor agonism with glucagon receptor-mediated effects on energy expenditure and hepatic metabolism. Gastrointestinal adverse events, including nausea, vomiting, and diarrhea, were common and were influenced by dose escalation. Phase 3 SYNCHRONIZE trials are evaluating efficacy, safety, and tolerability in broader populations with and without type 2 diabetes. Survodutide is not approved for routine clinical use, and its comparative effectiveness, durability, long-term safety, treatment persistence, and effects after discontinuation remain to be established.
Background
This paper addresses the efficacy and mechanism of Survodutide as a treatment for obesity. Prior studies have established the role of GLP-1 receptor agonists in weight management, but the dual action of Survodutide on glucagon receptors is a novel approach. Understanding its clinical evidence and uncertainties is crucial as it may provide new options for obesity treatment.
Methods
The study involved a phase 2 trial with adults having a body mass index ≥27 kg/m² without diabetes. Participants received a 4.8-mg dose of Survodutide over a duration of 46 weeks. Primary outcome measures included body weight reduction, with secondary outcomes related to safety and tolerability.
Results
The primary endpoint showed an 18.7% mean body-weight reduction at 46 weeks for the Survodutide group. The placebo group had a mean body-weight reduction of 2.3%. Adverse events, particularly gastrointestinal issues, were noted to be common and influenced by dose escalation.
Interpretation
The results indicate a statistically significant weight reduction with Survodutide compared to placebo; however, the clinical significance may be limited by the common occurrence of adverse events. The study's findings should be interpreted with caution due to the lack of long-term data and the potential for confounding factors. Further research is needed to establish the drug's comparative effectiveness and long-term safety.
Key findings
- 18.7% mean body-weight reduction at 46 weeks, n=not reported in abstract.
- 2.3% mean body-weight reduction with placebo at 46 weeks, n=not reported in abstract.
Limitations
- sample size not reported in abstract
- phase 2 trial, not definitive
- common gastrointestinal adverse events
- no long-term safety data
- not approved for routine clinical use